These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 23536337

  • 1. [New prospective on adjuvant treatment for gastrointestinal stromal tumors].
    Pan ZZ, Wu XJ.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
    [Abstract] [Full Text] [Related]

  • 10. [Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].
    Li SX, Li ZY, Zhang LH, Bu ZD, Wu AW, Wu XJ, Zong XL, Shan F, Ji X, Ji JF.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):226-9. PubMed ID: 23536340
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
    Pisters PW, Colombo C.
    J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
    [Abstract] [Full Text] [Related]

  • 12. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.
    Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
    [Abstract] [Full Text] [Related]

  • 13. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ.
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M, Taylor DC, Parthan A, Coombs J, Paolantonio M, Sasane M.
    J Med Econ; 2013 Jul; 16(1):150-9. PubMed ID: 22762291
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study.
    Hatoum HT, Lin SJ, Sasane M, Trent JC.
    Curr Med Res Opin; 2012 May; 28(5):805-14. PubMed ID: 22506625
    [Abstract] [Full Text] [Related]

  • 18. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
    Pandey R, Kochar R.
    J Gastrointest Cancer; 2012 Dec; 43(4):547-52. PubMed ID: 22847491
    [Abstract] [Full Text] [Related]

  • 19. Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification.
    Cananzi FC, Judson I, Lorenzi B, Benson C, Mudan S.
    Eur J Surg Oncol; 2013 Nov; 39(11):1171-8. PubMed ID: 24063969
    [Abstract] [Full Text] [Related]

  • 20. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.
    Digestion; 2013 Nov; 87(1):47-52. PubMed ID: 23343969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.